Head-To-Head Review: Pieris Pharmaceuticals (NASDAQ:PIRS) and Notable Labs (NASDAQ:NTBL)

Notable Labs (NASDAQ:NTBL) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Volatility & Risk

Notable Labs has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Insider & Institutional Ownership

70.5% of Notable Labs shares are owned by institutional investors. Comparatively, 40.1% of Pieris Pharmaceuticals shares are owned by institutional investors. 1.2% of Notable Labs shares are owned by company insiders. Comparatively, 8.9% of Pieris Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Notable Labs and Pieris Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Notable Labs	0	1	1	0	2.50
Pieris Pharmaceuticals	0	0	0	0	N/A

Notable Labs presently has a consensus price target of $7.00, indicating a potential upside of 2,792.56%. Given Notable Labs’ higher possible upside, equities analysts clearly believe Notable Labs is more favorable than Pieris Pharmaceuticals.

Earnings & Valuation

This table compares Notable Labs and Pieris Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Notable Labs	$313,000.00	6.97	-$11.26 million	N/A	N/A
Pieris Pharmaceuticals	$20.87 million	1.04	-$24.54 million	($11.95)	-1.38

Notable Labs has higher earnings, but lower revenue than Pieris Pharmaceuticals.

Profitability

This table compares Notable Labs and Pieris Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Notable Labs	N/A	-80.81%	-62.86%
Pieris Pharmaceuticals	-39.71%	-101.29%	-65.00%

Summary

Notable Labs beats Pieris Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

About Notable Labs

Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.